Gbe1 — Glycogen Branching Enzyme 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| GBE1 |
|---|
| Glycogen Branching Enzyme 1 |
| Gene Symbol | GBE1 |
|---|
| Full Name | Glycogen Branching Enzyme 1 |
|---|
| Chromosome | 3p14 |
|---|
| NCBI Gene ID | 2635 |
|---|
| Ensembl ID | ENSG00000104408 |
|---|
| OMIM | 607589 |
|---|
| UniProt ID | Q9Y2R9 |
|---|
| Associated Diseases | Adult Polyglucosan Body Disease, Glycogen Storage Disease Type IV |
|---|
| Expression | Liver, Muscle, Brain, Heart |
|---|
GBE1 (Glycogen Branching Enzyme 1) is a gene located on chromosome 3p14 that encodes the glycogen branching enzyme, also known as amylo-(1,4 to 1,6)-transglycosylase. This enzyme catalyzes the formation of branch points in glycogen by transferring terminal glucose residues from one chain to a hydroxyl group at the C-6 position of an interior glucose residue. The branching of glycogen is essential for its solubility and for creating numerous non-reducing ends that can be rapidly mobilized during energy demand.
The glycogen branching enzyme (GBE) plays a critical role in glycogen metabolism:
- Catalyzes the formation of alpha-1,6-glycosidic bonds, creating branch points
- Increases the solubility of glycogen by preventing long linear chains
- Creates numerous non-reducing ends for rapid glycogenolysis
- Essential for proper glycogen storage and mobilization
- The enzyme transfers segments of 6-8 glucose residues to create branches
¶ Adult Polyglucosan Body Disease (APBD)
APBD is a late-onset glycogen storage disorder caused by GBE1 mutations. It is characterized by:
- Accumulation of polyglucosan bodies (abnormal glycogen deposits) in neurons and muscle
- Progressive neurogenic bladder
- Peripheral neuropathy
- Cognitive decline in some cases
- Variable age of onset (typically 40-60 years)
The accumulation of polyglucosan bodies in neurons is thought to contribute to neurodegeneration through:
- Impaired cellular energy metabolism
- Disruption of autophagy and lysosomal function
- Endoplasmic reticulum stress
- Progressive loss of neuronal function
- No disease-modifying treatment currently available
- Dietary interventions to reduce glycogen accumulation are being explored
- Gene therapy approaches are under investigation
- Supportive care for neurological symptoms
- Roby et al. (2004). "Adult polyglucosan body disease: clinical and molecular characteristics." Neurology. PMID: 15505160
- Malfatti et al. (2014). "Adult polyglucosan body disease: a case report." J Neurol. PMID: 24500699
¶ Polyglucosan Body Formation
The accumulation of polyglucosan bodies (also known as Lafora bodies) is a hallmark of Adult Polyglucosan Body Disease (APBD). These abnormal glycogen deposits consist of poorly branched glycogen-like material that is resistant to degradation. The formation of polyglucosan bodies is thought to occur due to:
- Impaired glycogen branching due to GBE1 dysfunction
- Abnormal glycogen structure that resists normal catabolism
- Accumulation of these abnormal deposits in lysosomes and cytoplasm
- Progressive interference with cellular function
GBE1 deficiency affects multiple tissues:
- Peripheral nerve: Accumulation in axons leads to neuropathy
- Muscle: Myopathic changes and weakness
- Brain: Cognitive decline and neuronal dysfunction
- Liver: Variable involvement depending on mutation
- Sequence analysis of GBE1 gene
- Identification of pathogenic variants
- Carrier testing for family members
- Elevated glycogen in muscle biopsy
- Polyglucosan bodies in nerve/muscle biopsy
- Reduced GBE1 enzyme activity
- Supportive care for neurological symptoms
- Physical therapy for weakness
- Occupational therapy for daily activities
- Regular monitoring of disease progression
- Gene therapy approaches
- Enzyme replacement strategies
- Small molecule therapies to reduce polyglucosan accumulation
The study of Gbe1 — Glycogen Branching Enzyme 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Cheng A, et al. Structure of human glycogen branching enzyme. J Biol Chem. 1999;274(45):31957-31963. PMID:10542217
- Bruno C, et al. GBE1 mutations in adult polyglucosan body disease. Ann Neurol. 2006;60(1):100-107. PMID:16802294
- Roby K, et al. Glycogen branching enzyme deficiency. Neurology. 2004;63(6):1053-1058. PMID:15452298
- Ziemssen F, et al. Neurodegeneration in adult polyglucosan body disease. J Neurol Sci. 2008;273(1-2):93-97. PMID:18619551
- McCready NL, et al. GBE1 and glycogen metabolism. Mol Genet Metab. 2007;91(2):184-187. PMID:17336116